Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $755 from $958 and keeps an Overweight rating on the shares. Following the “mixed” Phase 3 COPD data for itepekimab, the firm removed the drug from its model, the analyst tells investors. The firm sees the current value of the stock as largely supported by Dupixent and the company’s cash, but adds that “execution is front and center” following the failed COPD study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron’s announces results of Phase 2 trial of semaglutide+trevogrumab
- Optimistic Outlook on Regeneron Despite Mixed AERIFY Trial Results
- Buy Rating Maintained for Regeneron Despite Mixed Trial Results, Driven by Promising Pipeline and Growth Prospects
- Regeneron price target lowered to $650 from $700 at Citi
- Regeneron announces analyses from Phase 3 C-Post trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue